| |
Normal
|
Non-AG
|
AG/IM
|
IEN/DYS
|
GC
|
P
|
|---|
|
Overall
|
760(31.91%)
|
1053(44.21%)
|
329(13.81%)
|
208(8.73%)
|
32(1.34%)
| |
|
Family History
| | | | | |
0.019
|
|
FDR-GC
|
394(29.65%)
|
599(45.07%)
|
190(14.30%)
|
126(9.48%)
|
20(1.50%)
| |
|
FDR-nGC
|
59(30.57%)
|
87(45.08%)
|
23(11.92%)
|
24(12.44%)
|
0(0.00%)
| |
|
FDR-nC
|
307(35.70%)
|
367(42.67%)
|
116(13.49%)
|
58(6.74%)
|
12(1.40%)
| |
|
Sex
| | | | | |
< 0.001
|
|
Male
|
287(29.77%)
|
412(42.74%)
|
127(13.17%)
|
117(12.14%)
|
21(2.18%)
| |
|
Female
|
473(33.36%)
|
641(45.20%)
|
202(14.25%)
|
91(6.42%)
|
11(0.78%)
| |
|
Age
|
57.92 ± 7.70
|
58.62 ± 7.52
|
60.05 ± 7.16
|
61.19 ± 6.33
|
62.50 ± 5.70
|
< 0.001
|
|
HP
| | | | | |
< 0.001
|
|
Positive
|
121(12.89%)
|
540(57.51%)
|
165(17.57%)
|
95(10.12%)
|
18(1.92%)
| |
|
Negative
|
639(44.28%)
|
513(35.55%)
|
164(11.37%)
|
113(7.83%)
|
14(0.97%)
| |
|
PGI/II
|
16.39 ± 7.41
|
12.78 ± 6.37
|
12.84 ± 7.13
|
13.68 ± 6.97
|
13.96 ± 11.56
|
< 0.001
|
|
Smoking
| | | | | |
< 0.001
|
|
Ever
|
171(27.58%)
|
261(42.10%)
|
82(13.23%)
|
90(14.52%)
|
16(2.58%)
| |
|
Never
|
589(33.43%)
|
792(44.95%)
|
247(14.02%)
|
118(6.70%)
|
16(0.91%)
| |
|
Drinking
| | | | | |
0.002
|
|
Ever
|
134(28.94%)
|
208(44.92%)
|
53(11.45%)
|
57(12.31%)
|
11(2.38%)
| |
|
Never
|
626(32.62%)
|
845(44.03%)
|
276(14.38%)
|
151(7.87%)
|
21(1.09%)
| |
|
High-Salt Diet
| | | | | |
0.699
|
|
Present
|
606(31.50%)
|
859(44.65%)
|
262(13.62%)
|
169(8.78%)
|
28(1.46%)
| |
|
Absent
|
154(33.62%)
|
194(42.36%)
|
67(14.63%)
|
39(8.52%)
|
4(0.87%)
| |
|
Tea
| | | | | |
0.011
|
|
Present
|
301(30.75%)
|
433(44.23%)
|
123(12.56%)
|
103(10.52%)
|
19(1.94%)
| |
|
Absent
|
459(32.72%)
|
620(44.19%)
|
206(14.68%)
|
105(7.48%)
|
13(0.93%)
| |
|
BMI
|
23.79 ± 2.88
|
24.51 ± 17.04
|
23.79 ± 2.97
|
23.81 ± 2.81
|
23.76 ± 3.08
|
0.687
|
|
Fruit/Vegetables
| | | | | |
0.760
|
|
≥ 3Times/Week
|
487(32.08%)
|
669(44.07%)
|
209(13.77%)
|
136(8.96%)
|
17(1.12%)
| |
|
< 3Times/Week
|
273(31.60%)
|
384(44.44%)
|
120(13.89%)
|
72(8.33%)
|
15(1.74%)
| |
|
Stage I
| | | | | |
< 0.001
|
|
Group A
|
158(38.16%)
|
154(37.20%)
|
63(15.22%)
|
35(8.45%)
|
4(0.97%)
| |
|
Group B
|
9(2.73%)
|
192(58.18%)
|
75(22.73%)
|
47(14.24%)
|
7(2.12%)
| |
|
Group C
|
3(7.50%)
|
23(57.50%)
|
9(22.50%)
|
5(12.50%)
|
0(0.00%)
| |
|
Group D
|
8(9.09%)
|
42(47.73%)
|
22(25.00%)
|
13(14.77%)
|
3(3.41%)
| |
|
Stage II
| | | | | |
< 0.001
|
|
Group A
|
407(50.56%)
|
268(33.29%)
|
67(8.32%)
|
57(7.08%)
|
6(0.75%)
| |
|
Group B
|
95(18.13%)
|
304(58.02%)
|
74(14.12%)
|
41(7.82%)
|
10(1.91%)
| |
|
Group C
|
14(31.11%)
|
21(46.67%)
|
7(15.56%)
|
2(4.44%)
|
1(2.22%)
| |
|
Group D
|
66(48.53%)
|
49(36.03%)
|
12(8.82%)
|
8(5.88%)
|
1(0.74%)
| |
- Abbreviations: AG atrophic gastritis, IM intestinal metaplasia, IEN intraepithelial neoplasia, DYS dysplasia, GC gastric cancer
- Stage I, the study from November 2016 to November 2017 at our digestive endoscopy center; Stage I, the study from February 2018 to September 2019 at our digestive endoscopy center. Group A: people with PG− and HP−; Group B: people with PG− and HP+; Group C: people with PG+ and HP+; Group D: people with PG+ and HP−
